Transnasal Testosterone Gel for Hypogonadism in Males with Allergic Rhinitis
Summary
USPTO published patent application US20260108531A1 by inventor Natalia Tkachenko on April 23, 2026, covering methods of treating hypogonadism in males via intranasal testosterone bio-adhesive gel formulations. The application discloses 4.0% and 4.5% testosterone gel compositions that remain effective when allergic rhinitis occurs or when topical nasal vasoconstrictors or decongestants are used during treatment. Filing date was March 20, 2025; application number 19085870.
“The present invention relates to methods of treating hypogonadism in a male subject through administering intranasally to the male subject an intranasal testosterone bio-adhesive gel formulation to deliver a therapeutically effective amount of testosterone.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108531A1 disclosing transnasal testosterone bio-adhesive gel formulations for treating hypogonadism in male subjects. The invention specifically addresses treatment scenarios where allergic rhinitis events occur or where topical nasal vasoconstrictors and intranasal decongestants are used concurrently. The gel formulations comprise 4.0% and 4.5% testosterone concentrations.
This document is a patent application publication, not a granted patent or regulatory action. It does not create compliance obligations for any party. Pharmaceutical companies researching testosterone delivery formulations or treating hypogonadism may review this application for competitive intelligence on formulation approaches that address allergic rhinitis interference.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of Treating Hypogonadism with Transnasal Testosterone Bio-adhesive Gel Formulations in Males with Allergic Rhinitis and Methods for Preventing an Allergic Rhinitis Event
Application US20260108531A1 Kind: A1 Apr 23, 2026
Inventors
Natalia Tkachenko
Abstract
The present invention relates to methods of treating hypogonadism in a male subject through administering intranasally to the male subject an intranasal testosterone bio-adhesive gel formulation to deliver a therapeutically effective amount of testosterone. In particular, the testosterone therapy of the invention remains effective if an allergic rhinitis event occurs in the male during the treatment or when the male subject uses a topical nasal vasoconstrictor or a topical intranasal decongestant during the hypogonadism treatment. Further, the present invention relates to a method of preventing Hie occurrence of an allergic rhinitis event in a male, who is undergoing a hypogonadism treatment with an intranasal testosterone bio-adhesive gel. In certain embodiments, the intranasal testosterone bio-adhesive gel formulation according to the invention comprises 4.0% and 4.5% testosterone.
CPC Classifications
A61K 31/568 A61K 9/0043 A61K 31/4174 A61P 15/00 A61P 37/08
Filing Date
2025-03-20
Application No.
19085870
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.